Tian-Tian Li1, Jun Li1, Ying-Hua Geng1, Feng Zhang1, Lin Liu1, Yan-Li Yang2. 1. Department of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, Anhui Province, China. 2. Department of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, Anhui Province, China,E-mail:yangyanli0702@126.com.
Abstract
OBJECTIVE: To investigate the mutation rate and distribution of Homo sapiens neuroblastoma RAS viral oncogene homolog (NRAS) gene in the patients with acute myeloid leukemia. METHODS: The genomic DNA of bone marrow was screened by polymerase chain reaction (PCR) and sequencing for NRAS mutations. At the same time, the mutations of ASXL1, DNMT3A, TET2, CEBPA, FLT3, IDH2, NPM1 and c-KIT genes were also detected to analyze the relation with NRAS mutations. RESULTS: A total of 11 NRAS mutations were found in 108 patients with initial acute myeloid leukemia and the mutation rate was 10.2%, including 6 cases of G12D, 3 cases of G13D, and 2 cases of G61K. In the mutation group, the peripheral blood leukocyte count was higher (P＜0.05), more likely to occur in the M4 subtype, and the M2 subtype was mutually exclusive (P＜0.05). Moreover, the mutant group was more likely to express CD13 than the non-mutation group (P＜0.05), while no statistic difference was found in age, gender, hemoglobin level, platelet count, lactate dehydrogenase level, bone marrow blast, cytogenetics, complete remission rate and overall survival (P＞0.05). CONCLUSIONS: The mutation of NRAS gene has no effect on the prognosis of AML patients.
OBJECTIVE: To investigate the mutation rate and distribution of Homo sapiensneuroblastoma RAS viral oncogene homolog (NRAS) gene in the patients with acute myeloid leukemia. METHODS: The genomic DNA of bone marrow was screened by polymerase chain reaction (PCR) and sequencing for NRAS mutations. At the same time, the mutations of ASXL1, DNMT3A, TET2, CEBPA, FLT3, IDH2, NPM1 and c-KIT genes were also detected to analyze the relation with NRAS mutations. RESULTS: A total of 11 NRAS mutations were found in 108 patients with initial acute myeloid leukemia and the mutation rate was 10.2%, including 6 cases of G12D, 3 cases of G13D, and 2 cases of G61K. In the mutation group, the peripheral blood leukocyte count was higher (P＜0.05), more likely to occur in the M4 subtype, and the M2 subtype was mutually exclusive (P＜0.05). Moreover, the mutant group was more likely to express CD13 than the non-mutation group (P＜0.05), while no statistic difference was found in age, gender, hemoglobin level, platelet count, lactate dehydrogenase level, bone marrow blast, cytogenetics, complete remission rate and overall survival (P＞0.05). CONCLUSIONS: The mutation of NRAS gene has no effect on the prognosis of AMLpatients.
Authors: Abdulaziz Asiri; Deemah Alwadaani; Muhammad Umair; Kheloud M Alhamoudi; Mohammed H Almuhanna; Abdul Nasir; Bahauddeen M Alrfaei; Abeer Al Tuwaijri; Tlili Barhoumi; Yusra Alyafee; Bader Almuzzaini; Mohammed Aldrees; Mariam Ballow; Latifah Alayyar; Abdulkareem Al Abdulrahman; Yazeid Alhaidan; Nahlah Al Ghasham; Sulaiman Al-Ajaji; Mohammad Alsalamah; Wafa Al Suwairi; Majid Alfadhel Journal: Genes (Basel) Date: 2021-02-20 Impact factor: 4.096